---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-003483"
form_type: "8-K"
ticker: "AGEN"
cik: "0001098972"
company_name: "AGENUS INC"
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T21:26:19.450567+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Agenus Q1 2022 net loss $51M; cash $263M; botensilimab to Phase 2; Gilead $5M milestone

## Summary
- Net loss of $51M ($0.19/share) vs $54M ($0.27/share) YoY; revenue $26M (up from $12M).
- Cash and short-term investments $263M, down from $307M at Dec 31, 2021; cash used in ops $52M.
- Botensilimab advancing to Phase 2 trials in colorectal, melanoma, pancreatic cancers; data in Q3 2022.
- AGEN1571 (ILT2) Phase 1 to start; AGEN2373 milestone of $5M from Gilead (up to $570M potential).
- Cost containment measures initiated to reduce operating expenses in coming quarters.

## SEC filing metadata
- accession: 0001171843-22-003483
- form_type: 8-K
- ticker: AGEN
- cik: 0001098972
- company_name: AGENUS INC
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1098972/000117184322003483/0001171843-22-003483-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1098972/000117184322003483/f8k_051022.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-003483
- JSON: https://secwatch.observer/filing/0001171843-22-003483.json
- Plain text: https://secwatch.observer/filing/0001171843-22-003483.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.